Literature DB >> 8751559

Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma.

F Carreiras1, Y Denoux, C Staedel, M Lehmann, F Sichel, P Gauduchon.   

Abstract

In an extension of a previous in vitro study [Carreiras et al., Int. J. Cancer 63, 530-536 (1995)] and in an effort to understand the adhesive interactions mediated by integrins within epithelial ovarian tumors, the presence of the alpha v and beta 3 subunits and that of vitronectin (Vn) in ovarian carcinomas at various stages of differentiation and in normal ovarian epithelium were comparatively investigated. The study was performed on material from 34 patients. By immunofluorescence, cryostat sections were analyzed for their expression of alpha v (34 cases), beta 3 (19 cases), and Vn (29 cases). alpha v was expressed in normal epithelium and in highly differentiated tumors as well as in a majority of moderately and poorly differentiated carcinomas with identical staining pattern. beta 3 subunit and Vn were also expressed in normal cases and highly differentiated carcinomas. However, they were lacking in most of the less differentiated tumors. The analysis of cases which were simultaneously tested for the presence of alpha v, beta 3, and Vn revealed that a large proportion of normal ovarian epithelium and highly differentiated tumors simultaneously expressed alpha v, beta 3, and Vn; in contrast, in all moderately and poorly differentiated carcinomas either beta 3 or Vn was absent. The potential role of the alpha v beta 3/Vn system in ovarian epithelium functions is discussed. It is also speculated that modifications of this system in ovarian carcinomas might contribute to tumor progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8751559     DOI: 10.1006/gyno.1996.0225

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  33 in total

1.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

2.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

3.  Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons.

Authors:  Dipanjan Pan; Manojit Pramanik; Angana Senpan; John S Allen; Huiying Zhang; Samuel A Wickline; Lihong V Wang; Gregory M Lanza
Journal:  FASEB J       Date:  2010-11-19       Impact factor: 5.191

4.  Instant immunity through chemically programmable vaccination and covalent self-assembly.

Authors:  Mikhail Popkov; Beatriz Gonzalez; Subhash C Sinha; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

5.  Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin.

Authors:  Sabrina Kellouche; Julien Fernandes; Johanne Leroy-Dudal; Olivier Gallet; Soizic Dutoit; Laurent Poulain; Franck Carreiras
Journal:  Tumour Biol       Date:  2010-02-24

6.  Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

Authors:  Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

7.  Expression of ADAM15 in lung carcinomas.

Authors:  A Schütz; W Härtig; M Wobus; J Grosche; Ch Wittekind; G Aust
Journal:  Virchows Arch       Date:  2005-03-09       Impact factor: 4.064

8.  Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.

Authors:  Ivo M B Francischetti; Michalis Kotsyfakis; John F Andersen; Jan Lukszo
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

9.  Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.

Authors:  Efrem Mebrahtu; Alexander Zheleznyak; Minjun A Hur; Richard Laforest; Suzanne E Lapi
Journal:  Nucl Med Biol       Date:  2012-11-12       Impact factor: 2.408

10.  External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas.

Authors:  Karolina Partheen; Kristina Levan; Lovisa Osterberg; Ingela Claesson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-09-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.